Introduction
POAG, blindness, glaucoma, vision impairment, Glaucoma
OCULAR HYPERTENSION, BLINDNESS, PGA, GLAUCOMA, GLAUCOMA
Glaucoma is the most common cause of irreversible blindness and the second most common cause of irreversible moderate and severe vision impairment worldwideThe choice of initial IOP-reducing therapy is essential for affecting the long-term outcome of glaucoma treatment. Prostaglandin analogue (PGA) monotherapy is often utilized as an initial treatment choice for POAG and ocular hypertension (OHT) because it is the most effective class of IOP-lowering drugsTherefore, in this study, we perform a prospective comparison between SLT and 0.005% latanoprost eye drops as first-line therapy in treatment-naïve POAG and OHT patients in a Chinese population. We hypothesize that primary 360° SLT will demonstrate a comparable 24-h IOP-lowering effect using latanoprost eye drops monotherapy as initial IOP-reducing therapy.